FDA moves to fast-track review of three psychedelic drug studies
The Hill
—
The Food and Drug Administration (FDA) on Friday granted fast-track review to three companies studying psychedelic therapies to treat depression and post-traumatic stress disorder (PTSD), the latest step by the Trump administration toward possible approval.
The agency did not disclose the specific companies that were granted priority review vouchers.
Two companies are studying psilocybin; one for treatment-resistant depression (TRD) and the other is studying treatment for major depressive disorder.
A third company is studying methylone, a…
- U.S. FDA plans ultra-fast review of three psychedelic drugs following Trump directive CTV News —
- US FDA plans ultra-fast review of 3 psychedelic drugs after Trump directive South China Morning Post —
- FDA grants quick review for 3 psychedelic drug trials NBC News —
- FDA fast-tracks psychedelic drug research following Trump executive order CNBC —
- FDA plans fast review of 3 psychedelic drugs following Trump directive Boston Globe —